Basic Colofac Information

• INN (International Nonproprietary Name): Mebeverine
• Brand Names Available In Canada (English): not specified
• ATC Code: A03AA04 — Drugs for functional gastrointestinal disorders, specifically synthetic anticholinergics, esters with tertiary amino group
• Forms & Dosages: Standard tablets 135 mg (1 tablet three times daily); Prolonged-release capsules 200 mg (1 capsule twice daily); Oral liquid for swallowing difficulties
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: OTC in some EU/UK pharmacies for small packs; prescription only in many other countries including Australia and much of Eastern Europe/Russia

Latest Research Highlights

Is mebeverine worth trying for IBS pain right now?

Recent meta-analyses and randomized trials from 2022–2025 continue to evaluate antispasmodics for irritable bowel syndrome.

Pooled data show mebeverine provides modest reductions in abdominal pain and cramping versus placebo.

Effect sizes vary between studies and there is notable heterogeneity in trial methods and outcome measures.

International pharmacovigilance continues to record a low incidence of serious adverse events for mebeverine.

Regulatory approvals and routine use remain stronger in Europe, the United Kingdom and Australasia than in North America.

Real data: INN = Mebeverine; ATC = A03AA04; common formulations include 135 mg tablets and 200 mg modified‑release capsules.

Safety signals data-highlight:

• Hypersensitivity reactions including rash and urticaria.
• Very rare central nervous system effects such as dizziness or tiredness.
• Occasional reports of false-positive urine amphetamine screens in selected assays.

Regulatory differences worth noting:

Colofac is OTC for some small packs in the UK, prescription-only in Australia, and more commonly marketed in Europe and Australasia than in North America.

Patient-centred note: Canadian patients prioritise a clear benefit-to-risk balance and want plain-language estimates of benefit.

Where possible, offer absolute risk differences from trials when counselling.

Cultural context: rural patients may face difficulty obtaining imported generics due to supply logistics.

Top Research Takeaways:

• Mebeverine shows modest, inconsistent pain reduction versus placebo across trials.
• Serious adverse events are rare in pharmacovigilance reports.
• Regulatory status varies internationally, with stronger approvals in Europe and Australasia than in Canada.

Clinical Effectiveness In Canada

Will mebeverine work the same way for Canadians as in UK or Australia trials?

Direct Canadian clinical trial data for mebeverine are limited.

Canadian clinicians therefore rely on international randomized controlled trials and pooled analyses to judge effectiveness.

Health Canada listing should be verified via the Drug Product Database for current NOC/DIN status before ordering or substituting.

Typical adult dosing from international product information is 135 mg three times daily or 200 mg modified‑release twice daily.

Patient-centred access advice:

Ask pharmacists at Shoppers Drug Mart, Rexall, London Drugs or Jean Coutu to check for a DIN or to explain if an import or generic is being used.

In Quebec, expect bilingual labelling and French-English patient leaflets under provincial and federal rules.

Provincial formularies may not list mebeverine directly.

Where absent, prescribers usually consider therapeutic alternatives on formularies or apply for Special Authorization or exceptional access.

Clinician actions checklist:

• Check Health Canada Drug Product Database for current registration and DIN.
• Consult the applicable provincial formulary (Ontario Drug Benefit, BC PharmaCare, RAMQ) for coverage options.
• Consider therapeutic substitutes if mebeverine is not listed or accessible locally.

Indications And Expanded Uses

Who is mebeverine for, and when is it used off‑label?

Primary indication internationally is symptomatic relief of abdominal pain and gut spasms in irritable bowel syndrome.

Off‑label uses include functional abdominal pain that does not meet full IBS criteria, post‑infectious spasmodic symptoms, and adjunctive therapy in chronic functional gastrointestinal disorders.

Evidence for off‑label uses is variable and generally weaker than for classic IBS symptom relief.

Approved Indications

Relief of abdominal pain, cramps and bowel irregularity in IBS.

Common Off‑Label Uses

Functional gut spasm, post‑infectious bowel spasm, adjunctive symptom control in chronic functional GI conditions.

Key patient counselling points:

Discuss clear symptomatic goals such as pain reduction and fewer spasms.

Agree on a review timeline, commonly reassess after about two weeks and consider longer trials of weeks to months if helpful.

Cultural note: some Indigenous and rural patients prefer non‑pharmacologic first-line measures.

Integrate mebeverine use with dietitian input, cognitive behavioural therapy or pelvic physiotherapy where available under public coverage.

Red Flags Requiring Immediate Review:

• Fever with abdominal pain.
• Any gastrointestinal bleeding or black stools.
• Unexplained weight loss or new severe vomiting.

Composition And Brand Landscape

What is in a Colofac tablet and where does it come from?

Active ingredient: mebeverine.

Typical global brands include Colofac (UK, Australia/NZ), Duspatalin (France), Duspatalin/Sparex (Russia/CIS) and generics from Mylan, Viatris and others.

Composition note:

Active ingredient is mebeverine; excipients vary by manufacturer so always check packaging and patient leaflets.

Packaging and supplier details commonly list originators such as Abbott and global generic manufacturers like Mylan/ViAtis, Teva, Sanofi and Zentiva.

Pricing and market access depend on which manufacturer supplies the Canadian pharmacy or whether a special import is used.

Patient tip:

If a patient asks for "Colofac" at the pharmacy, ask the pharmacy team to confirm the DIN and manufacturer.

Travellers should compare dosing and packaging conventions when bringing products from the UK or Australia.

Contraindications And Special Precautions

Who should not take mebeverine and what should pharmacists watch for?

Absolute contraindications include known hypersensitivity to mebeverine or any excipient and known paralytic ileus.

Certain formulations may be contraindicated in hereditary galactose intolerance, Lapp lactase deficiency or glucose‑galactose malabsorption.

Relative precautions apply in severe hepatic or renal impairment and acute porphyrias where data are limited.

Pregnancy and breastfeeding: international product information advises avoidance unless clinically necessary.

High‑Risk Groups For Canadian Clinical Practice:

• Elderly patients with polypharmacy.
• Patients with significant liver disease.
• Pregnant or breastfeeding people unless guided by a clinician.

Pharmacy practice note:

Ensure an allergy history and medication review are recorded at Shoppers Drug Mart, Rexall, London Drugs or Jean Coutu prior to dispensing.

Provide clear bilingual warnings for patients in Quebec and tailored safety advice for rural patients with slower emergency access.

Dosage Guidelines

How should mebeverine be taken, and what if a dose is missed?

Standard adult dosing internationally is either 135 mg tablet three times daily or 200 mg prolonged‑release capsule twice daily.

Pediatric and elderly guidance:

Not recommended for children under 10 years due to limited safety data.

Elderly patients generally use standard adult dosing unless clinical circumstances require change.

Storage and handling:

Store in original blister packaging below 25°C and protect from moisture and light.

Practical counselling tips:

• Advise taking as directed on the package leaflet; follow the specific product monograph when available.
• Recommend dose reminders for shift workers or patients in remote communities who may miss doses.
• Do not double the dose if a dose is missed.

Interactions Overview

Will mebeverine interact with common medicines or show up on tests?

Mebeverine has few well‑documented pharmacokinetic interactions with commonly used drugs.

Clinicians should still screen for additive central nervous system depression when used with other CNS depressants.

Other antispasmodics or anticholinergic agents can increase anticholinergic burden, although mebeverine itself lacks strong systemic anticholinergic action.

Relevant rare testing issue:

Mebeverine has been reported in rare cases to cause a false‑positive urine amphetamine screen on some immunoassays.

Advise confirmatory laboratory testing such as gas chromatography‑mass spectrometry if a workplace drug test is positive.

Interaction screening checklist:

• Ask about concurrent CNS depressants and other antispasmodics.
• Check for medications that increase anticholinergic load if the patient is sensitive.
• Discuss occupational drug testing and provide documentation for employers where needed.

Food and alcohol:

No major food interactions are recorded.

Caution with alcohol when other CNS‑active drugs are used concurrently.

Rural practice note:

In remote areas with limited access to confirmatory labs, caution patients about occupational risks until a confirmatory result is available.

Cultural Perceptions And Patient Habits

What do Canadian patients say about mebeverine and how do they actually use it?

Community sentiment in Canada is mixed with some patients reporting clear symptom relief and others preferring diet changes or natural remedies.

Mebeverine is often chosen when patients wish to avoid systemic anticholinergic side effects.

Many Canadians expect publicly funded, multimodal care combining pharmacotherapy with dietitian‑led advice or psychological therapies.

Urban versus rural access differences matter:

Urban patients typically have better access to specialists and private services.

Rural patients rely more on community pharmacists, telehealth and mail delivery from online pharmacies.

Common patient behaviours:

• Self‑medication with online purchases or imported products.
• Searching for Colofac 135 mg tablets online or via cross‑border suppliers.
• Preference for "natural" options such as peppermint oil among some patients.

Cross‑border note:

Some Canadians import products from the UK or US, but legal and safety implications apply and should be discussed at the pharmacy.

Availability And Pricing Patterns

How easy is it to buy Colofac in Canada and how much will it cost?

Colofac and mebeverine are widely available across the UK, Europe and Australia but have limited marketed presence in Canada.

Canadian retail chains may source generics by special order and online Canadian pharmacies vary in stock and prescription requirements.

In our online pharmacy, colofac is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Pricing considerations:

Prices vary by supplier and pack size and are generally influenced by import costs and manufacturer.

The United States has limited availability of mebeverine and cross‑border importing is subject to regulation.

Coverage:

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ may not list mebeverine and Special Authorization may be required.

Buying options:

• In‑store special order via major chains.
• Online Canadian pharmacy with prescription verification.
• Import from overseas suppliers under patient/prescriber direction.
• Therapeutic alternatives that are on provincial formularies.

Cultural note:

Cost sensitivity is common in Canada due to mixed public‑private coverage, and bilingual receipts and counselling are required in Quebec.

Comparable Medicines And Preferences

What are reasonable alternatives if mebeverine is unavailable or unsuitable?

Common alternatives used in Canada include dicycloverine (dicyclomine/Bentyl®), hyoscine butylbromide (Buscopan® in some markets), peppermint oil (Colpermin®) and alverine citrate.

Comparative evidence:

Mebeverine is often preferred for patients trying to avoid anticholinergic side effects because it does not show strong systemic anticholinergic action.

Peppermint oil has evidence for symptom relief in IBS for some patients but tolerability varies.

Practical checklist when choosing an alternative:

• Assess efficacy history and prior responses to antimuscarinics.
• Consider comorbid conditions such as glaucoma or urinary retention that increase anticholinergic risk.
• Check provincial formulary coverage for cost and access.

Patient counselling should include discussion of natural alternatives and how they fit with publicly funded care in Canada.

Frequently Asked Questions

• Q: Is Colofac available in Canada without a prescription?
  A: Availability is limited in Canada; unlike the UK OTC status for some packs, Colofac is not widely marketed here, so ask your pharmacy to check the Health Canada Drug Product Database and confirm DIN and coverage.
• Q: How fast does mebeverine work for IBS pain?
  A: Trials report symptom improvement within days to weeks, and a reassessment is reasonable after about two weeks if no benefit is seen.
• Q: Can pregnant or breastfeeding people take it?
  A: Use is generally avoided in pregnancy and breastfeeding unless a clinician advises otherwise and the benefits clearly outweigh potential risks.
• Q: Will it show up on drug tests?
  A: Very rarely mebeverine can cause a false‑positive amphetamine result on some urine immunoassays; request confirmatory laboratory testing if needed.
• Q: What if my province won’t cover it?
  A: Discuss therapeutic alternatives listed on provincial formularies or apply for Special Authorization with your prescriber to access mebeverine if clinically indicated.

Note: bilingual patient leaflets and telepharmacy options can help patients in remote communities access counselling when needed.

Guidelines For Proper Use

What should pharmacists and patients do to use mebeverine safely and effectively?

Follow international monographs and provincial policies when counselling and dispensing.

Storage: keep below 25°C in original blister packs and out of the reach of children.

Missed dose: take as soon as remembered unless it is near the next dose; do not double the dose.

Overdose: rarely serious; treat symptomatically and seek medical attention for severe symptoms.

Pharmacist checklist:

• Verify allergies and pregnancy/breastfeeding status.
• Review concomitant medications and occupational drug testing needs.
• Provide bilingual counselling and confirm the DIN and manufacturer if imported.
• Document Special Authorization requests for provincial formularies such as ODB, PharmaCare or RAMQ.

Equity considerations:

Offer clear, plain‑language counselling and involve Indigenous health liaisons when available.

For rural patients, suggest telepharmacy follow‑up to monitor benefit and adverse effects.

Clinician ending note:

Use shared decision‑making, document outcomes, and support coverage requests with clinical notes when appropriate.

Delivery Across Canada (English)